Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SPTX
STRONG SELLSeaport Therapeutics, Inc. · Healthcare · United States · $1.1B · Avg Vol: $4M/d
8
StockRankGet insider-trade alerts
Q
34
V
25
M
23
P/E (TTM)
—
ROE
—
D/E
0.0x
Dividend %
—
Loading 1Y...
PRICE (1Y)+14.1%
SMA 50SMA 200
Close
$20.54
RSI (14)
59.6
SCORE BREAKDOWN
Quality
34
ROIC
-37.0%20.5
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-31.4%10.3
Piotroski
239.0
Int. Cover
—N/A
D/E Ratio
0.03x77.4
Current Ratio
13.24x90.8
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-13.3x25.0
P/FCF
—N/A
P/B
-0.5x25.0
P/S
—N/A
Div Yield
—N/A
Momentum
23
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-50%9.3
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.1B
P/E (Forward)
-8.6x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SPTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SPTX | Seaport Therapeutics, Inc.(you) | $1.1B | 8 | STRONG SELL |
| AVLN | Avalyn Pharma Inc. | $1.2B | 9 | STRONG SELL |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.1B | 11 | STRONG SELL |
| CAPR | Capricor Therapeutics, Inc. | $1.1B | 11 | STRONG SELL |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.2B | 7 | STRONG SELL |
| INBX | Inhibrx Biosciences, Inc. | $1.2B | 10 | STRONG SELL |
| OLMA | Olema Pharmaceuticals, Inc. | $1.0B | 10 | STRONG SELL |
| AKTS | Aktis Oncology, Inc. | $1.3B | 10 | STRONG SELL |
| SANA | Sana Biotechnology, Inc. | $885M | 10 | STRONG SELL |
| EYPT | EyePoint, Inc. | $1.0B | 3 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%